51. Yoshio H, Shimizu M, Kita Y. Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X. J Am Coll Cardiol. 1995;25:147–51.
52. Elliott PM, Krzyzowska-Dickinson K, Calvino R, Hann C, Kaski JC. Effect of oral aminophylline in patients with angina and normal coronary arteriograms (syndrome X). Heart. 1997;77:523–6.
53. Pizzi C, Manfrini O, Fontana F, Bugiardini R. Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac syndrome X: role of superoxide dismutase activity. Circulation. 2004;109:53–8.
54. Pauly DF, Johnson BD, Anderson RD. In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2011;162:678–84.
55. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol. 1994;23:652–7.
56. Nalbantgil I, Onder R, Altintig A. Therapeutic benefits of cilazapril in patients with syndromeX. Cardiology. 1998;89:130–3.
57. Chen JW, Hsu NW, Wu TC. Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002;90:974–82.
58. Camici P, Marracini P, Gistri R. Adrenergically mediated coronary vasoconstriction in patients with syndrome X. Cardiovasc Drugs Ther. 1994;8:221–6.
59. Rosen SD, Lorenzoni R, Kaski JC, Foale RA, Camici PG. Effect of alpha1-adrenoceptor blockade on coronary vasodilator reserve in cardiac syndrome X. J Cardiovasc Pharmacol. 1999;34:554–60.
60. Galassi AR, Kaski JC, Pupita G, Vejar M, Crea F, Maseri A. Lack of evidence for alpha-adrenergic receptor-mediated mechanisms in the genesis of ischemia in syndrome X. Am J Cardiol. 1989;64:264–9.
61. Chen JW, Lee WL, Hsu NW. Effects of short-term treatment of nicorandil on exercise-induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol. 1997;80:32–8.
62. Yamabe H, Namura H, Yano T. Effect of nicorandil on abnormal coronary flow reserve assessed by exercise 201Tl scintigraphy in patients with angina pectoris and nearly normal coronary arteriograms. Cardiovasc Drugs Ther. 1995;9:755–61.
63. Nalbantgil S, Altinti A, Yilmaz H, Nalbantgil II, Önder R. The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol. 1999;8:40–3.
64. Fábián E, Varga A, Picano E, Vajo Z, Rónaszéki A, Csanády M. Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol. 2004;94:652–5.
65. Kayikcioglu M, Payzin S, Yavuzgil O, Kultursay H, Can LH, Soydan I. Benefits of statin treatment in cardiac syndrome-X. Eur Heart J. 2003;24:1999–2005.
66. Collins P. Role of endothelial dysfunction and oestrogens in syndrome X. Coron Artery Dis. 1992;3:593–8.
67. Rosano GMC, Peters NS, Lefroy D. Symptomatic response to 17β-estradiol in women with syndrome X. J Am Coll Cardiol. 1996;28:1500–5.
68. Albertsson PA, Emanuelsson H, Milsom I. Beneficial effect of treatment with transdermal estradiol-17-beta on exercise-induced angina and ST segment depression in syndrome X. Int J Cardiol. 1996;54:13–20.
69. Jhund PS, Dawson N, Davie AP. Attenuation of endothelin-1 induced vasoconstriction by 17beta estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. J Am Coll Cardiol. 2001;37:1367–73.
70. Anderson GL, Limacher M, Assaf AR. Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12.
71. Cannon RO 3rd, Quyyumi AA, Mincemoyer R. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330:1411–7.
72. Cox ID, Hann CM, Kaski JC. Low dose imipramine improves chest pain but not quality of life in patients with angina and normal coronary angiograms. Eur Heart J. 1998;19:250–4.
73. Norrsell H, Eliasson T, Mannheimer C. Effects of pacing-induced myocardial stress and spinal cord stimulation on whole body and cardiac norepinephrine spillover. Eur Heart J. 1997;18:1890–6.
74. Eliasson T, Albertsson P, Ha°rdhammar P, Emanuelsson H, Augustinsson LE, Mannheimer C. Spinal cord stimulation in angina pectoris with normal coronary arteriograms. Coron Artery Dis. 1993;4:819–27.
75. Lanza GA, Sestito A, Sandric S. Spinal cord stimulation in patients with refractory anginal pain and normal coronary arteries. Italian Heart J. 2001;2:25–30.
76. Lanza GA, Sestito A, Sgueglia GA. Effect of spinal cord stimulation on spontaneous and stress-induced angina and ‘ischemia-like’ ST-segment depression in patients with cardiac syndrome X. Eur Heart J. 2005;26:983–9.
77. Sgueglia GA, Sestito A, Spinelli A. Long-term follow-up of patients with cardiac syndrome X treated by spinal cord stimulation. Heart. 2007;93:591–7.
78. Kitsou V, Xanthos T, Roberts R, Karlis GM, Padadimitriou L. Enhanced external counterpulsation: mechanisms of action and clinical applications. Acta Cardiol. 2010;65:239–47.
79. Kronhaus KD, Lawson WE. Enhanced external counterpulsation is an effective treatment for Syndrome X. Int J Cardiol. 2009;135:256–7.
80. LanzaGA. Alternative treatments for angina.Heart. 2007;93:544–6.
81. Asbury EA, Slattery C, Grant A, Evans L, Barbir M, Collins P. Cardiac rehabilitation for the treatment of women with chest pain and normal coronary arteries. Menopause. 2008;15:454–60.
82. Bass C, Wade C. Chest pain with normal coronary arteries: a comparative study of psychiatric and social morbidity. Psychol Med. 1984;14:51–61.
83. Potts SG, Lewin R, Fox KAA, Johnstone EC, Cay EL. Group psychological treatment for chest pain with normal coronary arteries: a controlled trial. QJM. 1999;92:81–6.